5α-Reductase Inhibitors Could Prevent the Clinical and Pathological Progression of Prostate Cancer: A Meta-analysis
Vol. 18 No. 03 (2021),
Purpose: To explore the efficacy of 5-ARIs in PCA (Prostate Cancer).
Methods: Searching through the major medical databases such as PubMed, Science Citation Index, EMBASE,
Medline, Web of Science, Cochrane Library for all published studies in English until 2018. The following search
terms were used: “Finasteride”, “dutasteride”, “5α reductase inhibitors”, “5-ARIs”, “prostate cancer”, “prostate
neoplasm” and the additional related studies were manually searched. Newcastle-Ottawa Scale (NOS) assessed the qualities of studies, and the outcome measures were observed by RR or OR with 95% CIs.
Results: We included 9 eligible studies for analyses from 2011 to 2017. We found that 5-ARIs group may have
fewer progression (OR = 0.48 95%CI: 0.37-0.61 P < 0.00001, I2=4% p = 0.39) and lower pathological progression
(OR = 0.46; 95%CI: 0.29-0.73; p = 0.001, I2=0% p = 0.45), compared with control groups. However, the OS did
not show significant difference between two groups (OR=1.10; 95%CI:0.90-1.35; P = 0.35, I2 = 93% P < .00001 ).
Conclusion: The use of 5-ARIs could prevent progression in PCA patients both clinical and pathological.
- Prostate Cancer
How to Cite
Hoque A, Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, et al: Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease. Urology 85:616-20, 2015
Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, Goodman PJ, Thompson IJ: Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. J Natl Cancer Inst, 2018
Murtola TJ, Kujala PM, Tammela TL: High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5alpha-reductase inhibitors and alpha-blockers. Prostate 73:923-31, 2013
Montironi R, Bartels PH, DeCensi A, Puntoni M, Hurle R, Decobelli O, Carmignani G, Mazzucchelli R, Bartels HG, et al: A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. Urol Oncol 31:557-65, 2013
Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet 379:1103-11, 2012
Azoulay L, Eberg M, Benayoun S, Pollak M: 5alpha-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. JAMA Oncol 1:314-20, 2015
Dai C, Ganesan V, Zabell J, Nyame YA, Almassi N, Greene DJ, Hettel D, Reichard C, Haywood SC, et al: Impact of 5alpha-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features. J Urol 199:445-452, 2018
Schroder F, Bangma C, Angulo JC, Alcaraz A, Colombel M, McNicholas T, Tammela TL, Nandy I, Castro R: Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS). Eur Urol 63:779-87, 2013
Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM: Effect of treatment with 5-alpha reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. BJU Int 110:651-7, 2012
Wong LM, Fleshner N, Finelli A: Impact of 5-alpha reductase inhibitors on men followed by active surveillance for prostate cancer: a time-dependent covariate reanalysis. Eur Urol 64:343, 2013
Kjellman A, Friis S, Granath F, Gustafsson O, Sorensen HT, Akre O: Treatment with finasteride and prostate cancer survival. Scand J Urol 47:265-71, 2013
Unger JM, Till C, Thompson IJ, Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, et al: Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 108, 2016
Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, et al: Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99:1375-83, 2007
Kulkarni GS, Al-Azab R, Lockwood G, Toi A, Evans A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE: Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 175:505-9, 2006
Murtola TJ, Karppa EK, Taari K, Talala K, Tammela TL, Auvinen A: 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. Int J Cancer 138:2820-8, 2016
Orsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG: Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. Eur Urol 60:691-8, 2011
- Abstract Viewed: 0 times
- 4831/pdf Downloaded: 0 times